What is claimed is:
1. A control method of a powered sliding device which slides, in a door opening direction and in a door closing direction by power of a motor, a vehicle sliding door which is kept in a door-open position set through a specified width X in the door closing direction from a mechanical door-open end DOE by overcoming resistance of an overcoming holding type door holder after the door is slid to the door-open end DOE, wherein the power of the motor is suppressed when the sliding door reaches an opening speed final decelerating position FDP set on a door opening side of a maximum resistance position MRP of the door holder by the door opening power of the motor: comprising the steps of;
setting a switching point where a holder switch for detecting entering to the door-open position of the sliding door and separation from the door-open position is switched, to a holder check point HCP;
setting the final decelerating position FDP to a position separated from the door-open end DOE to the door closing side by a specified distance Z;
measuring a distance Y from the holder check point HCP to the door-open end DOE on the basis of a sliding quantity of the sliding door when the sliding door reaches the door-open end DOE after the door passes the holder check point HCP by the door opening power of the motor;
finding a proper value of a distance Z from the holder check point HCP to the final decelerating position FDP by calculation from the distance Y found from the sliding quantity of the sliding door and the specified distance Z between the final decelerating position FDP and the door opening end position DOE; and
considering that the sliding door reaches the final decelerating position FDP, when the sliding door slides by the distance Z after passing the holder check point HCP by door opening power of the motor.
2. The control method according to claim 1, wherein the distance Y is measured each time the door opening operation of the sliding door is performed.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
We claim:
1. A method of detecting the presence of a target BS325 polynucleotide in a test sample, said method comprising:
(a) contacting the test sample with at least one BS325-specific polynucleotide or complement thereof, wherein said BS325-specific polynucleotide has at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NOS 1-10, and fragments or complements thereof; and
(b) detecting the presence of target BS325 polynucleotides from the test sample which bind to said BS325-specific polynucleotide.
2. The method of claim 1, wherein said target BS325 polynucleotide is attached to a solid phase prior to performing step (a).
3. The method of claim 1, wherein said BS325-specific polynucleotide is attached to a solid phase prior to performing step (a).
4. A method for detecting BS325 mRNA in a test sample, said method comprising:
(a) performing reverse transcription on said sample using at least one primer in order to produce cDNA;
(b) amplifying the cDNA obtained from step (a) using BS325 oligonucleotides as sense and antisense primers to obtain BS325 amplicon; and
(c) detecting the presence of said BS325 amplicon, wherein the BS325 oligonucleotides utilized in steps (a) and (b) have at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-10, and fragments or complements thereof.
5. The method of claim 4, wherein said test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).
6. The method of claim 4, wherein said detection step comprises utilizing a detectable label capable of generating a measurable signal.
7. A method of detecting a target BS325 polynucleotide in a test sample suspected of containing said target polynucleotide, comprising:
(a) contacting the test sample with at least one BS325 oligonucleotide as a sense primer and with at least one BS325 oligonucleotide as an anti-sense primer and amplifying to obtain a first stage reaction product;
(b) contacting said first stage reaction product with at least one other BS325 oligonucleotide to obtain a second stage reaction product, with the proviso that the other BS325 oligonucleotide is located 3 to the BS325 oligonucleotides utilized in step (a) and is complementary to said first stage reaction product; and
(c) detecting said second stage reaction product as an indication of the presence of the target BS325 polynucleotide, wherein the BS325 oligonucleotides utilized in steps (a) and (b) have at least 50% identity with a sequence selected from the group consisting SEQUENCE ID NOS 1-10, and fragments or complements thereof.
8. The method of claim 7, wherein said test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).
9. The method of claim 7, wherein said detection step comprises utilizing a detectable label capable of generating a measurable signal.
10. The method of claim 9, wherein said detectable label is reacted to a solid phase.
11. A test kit useful for detecting BS325 polynucleotide in a test sample, said test kit comprising a container containing at least one BS325 polynucleotide having at least 50% identity with a sequence selected from the group consisting SEQUENCE ID NOS 1-10, and fragments or complements thereof.
12. A purified polynucleotide derived from a BS325 nucleic acid molecule, wherein said polynucleotide has at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-10, and fragments or complements thereof.
13. The polynucleotide of claim 12, wherein said polynucleotide hybridizes selectively to a BS325 nucleic acid sequence.
14. The polynucleotide of claim 12, wherein said polynucleotide has an overall length of about 20 to about 50 nucleotides.
15. The polynucleotide of claim 12, wherein said polynucleotide has an overall length of about 10 to about 25 nucleotides.
16. The polynucleotide of claim 12, wherein said polynucleotide is produced by recombinant techniques.
17. The polynucleotide of claim 12, wherein said polynucleotide is produced by synthetic techniques.
18. The polynucleotide of claim 12, wherein said polynucleotide comprises a sequence encoding at least one BS325 epitope.
19. The polynucleotide of claim 12, wherein said polynucleotide is attached to a solid phase.
20. The polynucleotide of claim 19, wherein said solid phase comprises an array of polynucleotide molecules attached thereto.
21. A recombinant expression system comprising a nucleic acid sequence that includes an open reading frame derived from a BS325 polynucleotide, wherein said open reading frame is operably linked to a control sequence compatible with a desired host, and said nucleic acid sequence has at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-10, and fragments or complements thereof.
22. A cell transfected with the recombinant expression system of claim 21.
23. A BS325 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
24. The polypeptide of claim 23, wherein said polypeptide is produced by recombinant techniques.
25. The polypeptide of claim 23, wherein said polypeptide is produced by synthetic techniques.
26. A specific binding molecule that binds to at least one BS325 epitope, wherein said BS325 epitope is derived from an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
27. The specific binding molecule of claim 26, wherein said molecule is an antibody molecule.
28. A test kit for determining the presence of BS325 antigen or anti-BS325 antibody in a test sample, said kit comprising a container containing a BS325 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
29. The test kit of claim 28, wherein said BS325 polypeptide is attached to a solid phase.
30. A test kit for determining the presence of BS325 antigen in a test sample, said kit comprising a container containing a specific binding molecule which binds to a BS325 antigen having at least one BS325 epitope.
31. The kit of claim 30, wherein said specific binding molecule is attached to a solid phase.
32. A method for producing a polypeptide comprising at least one BS325 epitope, said method comprising incubating host cells that have been transfected with an expression vector containing a polynucleotide sequence encoding a polypeptide, wherein said polypeptide comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
33. A method for detecting BS325 antigen in a test sample suspected of containing said BS325 antigen, comprising:
(a) contacting the test sample with a specific binding molecule which binds to at least one epitope of a BS325 antigen selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof, wherein said contacting is performed for a time and under conditions sufficient for the formation of binding moleculeantigen complexes; and
(b) detecting the presence of said complexes as an indication of the presence of said BS325 antigen.
34. The method of claim 33, wherein said specific binding molecule is an antibody molecule or a fragment thereof.
35. The method of claim 33, wherein said specific binding molecule is attached to a solid phase.
36. A method for detecting the presence of antibodies specific for a BS325 antigen in a test sample suspected of containing such antibodies, said method comprising:
(a) contacting the test sample with a BS325 polypeptide, wherein said BS325 polypeptide contains at least one BS325 epitope derived from an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof, and further wherein said contacting is performed for a time and under conditions sufficient to allow antigenantibody complexes to form; and
(b) detecting the presence of said complexes as an indication of the presence of antibodies specific for a BS325 antigen.
37. The method of claim 36, wherein said BS325 polypeptide is attached to a solid phase.
38. A cell transfected with a nucleic acid sequence encoding at least one BS325 epitope, wherein said nucleic acid sequence is selected from the group consisting of SEQUENCE ID NOS 1-10, and fragments or complements thereof.
39. A method for producing antibodies that specifically bind to BS325 antigen, comprising administering to an individual an isolated immunogenic polypeptide or fragment thereof in an amount sufficient to elicit an immune response, wherein said immunogenic polypeptide comprises at least one BS325 epitope and has at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
40. A method for producing antibodies that specifically bind to BS325 antigen, comprising administering to an individual a plasmid comprising a sequence that encodes at least one BS325 epitope derived from a polypeptide having an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
41. The test kit of claim 11 further comprising a container with tools useful for collection of said sample, wherein the tools are selected from the group consisting of lancets, absorbent paper, cloth, swabs and cups.
42. The test kit of claim 28 further comprising a container with tools useful for collection of said sample, wherein the tools are selected from the group consisting of lancets, absorbent paper, cloth, swabs and cups.
43. The test kit of claim 30 further comprising a container with tools useful for collection of said sample, wherein the tools are selected from the group consisting of lancets, absorbent paper, cloth, swabs and cups.
44. The test kit of claim 30, wherein said specific binding molecule is an antibody or fragment thereof.
45. The polynucleotide of claim 12, wherein said polynucleotide codes for a BS325 protein which comprises an amino acid sequence having at least 50% identity to SEQUENCE ID NO 19.
46. The polynucleotide of claim 12, wherein said polynucleotide comprises DNA having at least 50% identity with SEQUENCE ID NO 9 or SEQUENCE ID NO 10.
47. The method of claim 1, wherein the presence of said target BS325 polynucleotide in the test sample is indicative of breast disease.
48. The method of claim 4, wherein the presence of said amplicon is indicative of breast disease.
49. The method of claim 7, wherein the presence of said second stage reaction product is indicative of breast disease.
50. The method of claim 33, wherein detection of said complexes is indicative of breast disease.
51. The method of claim 36, wherein detection of said complexes is indicative of breast disease.